2-Methyl-6-tert.-butyl-hydrochinon | 2349-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-6-tert.-butyl-hydrochinon
• 英文别名: 2-tert-butyl-6-methylhydroquinone；2-T-Butyl-6-methylhydroquinone；2-tert-butyl-6-methylbenzene-1,4-diol
• CAS: 2349-84-0
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: LMIQZMJKGJNJLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Methyl-6-tert.-butyl-hydrochinon 在 盐酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.33h， 生成 5-Methyl-7-tert-butyltocopherol
  参考文献：
  名称：

  Synthesis and kinetic study of antioxidant activity of new tocopherol (vitamin E) compounds

  摘要：

  DOI：

  10.1021/jo00264a010
• 作为产物：
  描述：

  2-叔丁基-6-甲基苯酚 生成 2-Methyl-6-tert.-butyl-hydrochinon
  参考文献：
  名称：

  Petranek,J.; Pilar,J., Collection of Czechoslovak Chemical Communications, 1970, vol. 35, p. 830 - 837

  摘要：

  DOI：

文献信息

• 4-Hydroxytetrahydropyran-2-one derivatives
  申请人：Fujirebio Inc.

  公开号：US05149834A1

  公开（公告）日：1992-09-22

  4-hydroxytetrahydropyran-2-one derivatives with general formula (I) are useful as cholesterol reducing agents as well as lipid reducing agents, serving as inhibitors of HMG-CoA reductase, and capable of inhibiting the biosynthesis of peroxidized lipids, and therefore effective for curing arteriosclerosis: ##STR1## wherein R.sub.1 represent hydrogen or a 2-tetrahydropyranyl group; R.sub.2 and R.sub.3 each represent hydrogen or an alkyl group having 1 to 6 carbon atoms; R.sub.4 represents hydrogen, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an aryl group, an aralkyl group, an acyl group, an aroyl group or a substituted sulfonyl group; A represents --CH.sub.2 CH.sub.2 --, or --CH.dbd.CH--; and n is an integer of 1 or 2, and intermediates for synthesizing the 4-hydroxytetrahydropyran-2-one derivatives are disclosed.

  具有一般式(I)的4-羟基四氢吡喃-2-酮衍生物可用作降低胆固醇和脂质的药剂，作为HMG-CoA还原酶的抑制剂，能够抑制过氧化脂质的生物合成，因此对治疗动脉硬化有效：其中R.sub.1代表氢或2-四氢吡喃基团；R.sub.2和R.sub.3各代表氢或具有1至6个碳原子的烷基基团；R.sub.4代表氢，具有1至6个碳原子的烷基基团，具有2至6个碳原子的烯基基团，芳基，芳基烷基，酰基，芳基酰基或取代磺酰基；A代表--CH.sub.2 CH.sub.2--或--CH.dbd.CH--; n为1或2的整数，公开了用于合成4-羟基四氢吡喃-2-酮衍生物的中间体。
• HETEROCYCLIC COMPOUND AND ELECTRONIC APPARATUS
  申请人：Samsung Display Co., Ltd.

  公开号：US20190229290A1

  公开（公告）日：2019-07-25

  Provided are a heterocyclic compound and an electronic apparatus. The electronic apparatus includes: a substrate; an organic light-emitting device on the substrate; and a thin film encapsulation portion sealing the organic light-emitting device, the thin film encapsulation portion including an ultraviolet (UV) stabilizing mixture, and the UV stabilizing mixture including a UV absorbent and a radical scavenger.

  提供的是一种杂环化合物和一种电子设备。该电子设备包括：基板；设置在基板上的有机发光器件；以及用于封装有机发光器件的薄膜封装部分，薄膜封装部分包括紫外（UV）稳定混合物，该UV稳定混合物包括UV吸收剂和自由基清除剂。
• Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
  申请人：Miller M. Guy

  公开号：US20070072943A1

  公开（公告）日：2007-03-29

  Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.

  本发明公开了治疗或抑制线粒体疾病的方法，例如弗里德雷希共济失调症（FRDA）、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）或科恩斯-萨耶综合症（KSS），以及在本发明方法中有用的化合物。本发明还公开了评估受试者代谢状态和治疗效果有用的能量生物标志物。
• Preparation and ESR Studies of New Stable Tocopheroxyl Model Radicals
  作者：Kazuo Mukai、Kimiko Takamatsu、Kazuhiko Ishizu

  DOI：10.1246/bcsj.57.3507

  日期：1984.12

  tocopheroxyl radicals obtained from the above tocopherol model compounds by oxidizing the phenol precursors with PbO2 in toluene. The proton hyperfine coupling constants and giso-values were determined. The tocopheroxyl radicals 2 and 3 having large alkyl substituents at both ortho positions (C-5 and C-7) are fairly stable, and the radical stability, as measured by the intensities of the ESR signals, increases

  新的生育酚（维生素 E）模型化合物（生育酚 1；7-t-丁基-2,2-二甲基-6-色素醇、生育酚 2；7-t-丁基-2,2,5-三甲基-6-色素醇和生育酚 3; 5,7-二异丙基-2,2-二甲基-6-苯并苯二酚）是通过 2-甲基-3-丁烯-2-醇与相应的烷基氢醌缩合合成的。通过在甲苯中用 PbO 2 氧化苯酚前体，对从上述生育酚模型化合物获得的生育酚自由基进行电子自旋共振测量。确定了质子超精细耦合常数和 giso 值。在两个邻位（C-5 和 C-7）具有大烷基取代基的生育酚自由基 2 和 3 相当稳定，并且自由基稳定性（通过 ESR 信号的强度测量）以生育酚 1<α 的顺序增加-生育酚模型
• Preparation of Organosilicon Compound Having (Meth)acryloyloxy Group
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：US20210139515A1

  公开（公告）日：2021-05-13

  A (meth)acryloyloxy-containing organosilicon compound (3) is prepared by simultaneously feeding a hydrohalosilane compound (1) and a (meth)acrylate compound (2) in the presence of a polymerization inhibitor to a reaction system, and effecting hydrosilylation reaction in the presence of a platinum catalyst. The content of (meth)acrylate compound (2) is 0-100 mol % based on the content of organosilicon compound (3) in the reaction system. R is a C 1 -C 10 monovalent hydrocarbon group, X is halogen, n is 1, 2 or 3, R 2 is H or methyl, and R 3 is a C 1 -C 18 alkylene group.

  通过在聚合抑制剂的存在下同时加入羟卤代硅烷化合物（1）和（甲基）丙烯酸酯化合物（2）到反应体系中，利用铂催化剂进行氢硅烷化反应，制备含有（甲基）丙烯酰氧基的有机硅化合物（3）。在反应体系中，（甲基）丙烯酸酯化合物（2）的含量基于有机硅化合物（3）的含量为0-100摩尔％。其中，R是C1-C10一价烃基，X是卤素，n为1、2或3，R2为氢或甲基，R3为C1-C18烷基。